|
|
||||||||
Investigative Ophthalmology & Visual Science, Vol 38, 817-823, Copyright © 1997 by Association for Research in Vision and Ophthalmology
ARTICLES AND REPORTS |
B Anand-Apte, MS Pepper, E Voest, R Montesano, B Olsen, G Murphy, SS Apte and B Zetter
Department of Surgical Research, Children's Hospital, Boston, Massachusetts, USA.
PURPOSE: It has been established that Sorsby's fundus dystrophy, a dominantly inherited form of blindness, is caused by mutations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) gene. Because choroidal neovascularization is a prominent feature of Sorsby's fundus dystrophy, the authors have examined whether TIMP-3 protein plays a role in the regulation of angiogenesis. METHODS: Chemotaxis of endothelial cells toward vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) was examined using a modified Boyden chamber assay. Endothelial cells placed in the upper chamber were allowed to migrate through a polycarbonate membrane with 8 microns pores toward VEGF or bFGF present in the lower chamber. Next, the ability of TIMP-3 to inhibit chemotaxis was studied by incubating the cells with varying amounts of TIMP-3 during the assay. Finally, an in vitro angiogenesis assay was performed on collagen gels. Endothelial cells were seeded onto three-dimensional collagen gels. Treatment with bFGF and VEGF induced invasion of the gel and the formation of tube- like structures. TIMPs (1, 2, and 3) were added to the cultures to determine their effect on invasion. An in vivo chorioallantoic membrane (CAM) assay was performed using methylcellulose discs containing bFGF with or without TIMP-3. Induction of new blood vessels was observed with a stereomicroscope. RESULTS: TIMP-3 inhibits chemotaxis of vascular endothelial cells toward VEGF and bFGF, inhibits collagen gel invasion and capillary morphogenesis in vitro, and inhibits bFGF- induced angiogenesis in the CAM assay in vivo. CONCLUSIONS: TIMP-3 has the potential to inhibit angiogenesis. These results allow us to speculate on a possible mechanism by which mutant TIMP-3 protein might contribute to the Sorsby fundus dystrophy phenotype.
This article has been cited by other articles:
![]() |
W. G. Stetler-Stevenson Tissue Inhibitors of Metalloproteinases in Cell Signaling: Metalloproteinase-Independent Biological Activities Sci. Signal., July 8, 2008; 1(27): re6 - re6. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Janssen, J. Hoellenriegel, M. Fogarasi, H. Schrewe, M. Seeliger, E. Tamm, A. Ohlmann, C. A. May, B. H. F. Weber, and H. Stohr Abnormal Vessel Formation in the Choroid of Mice Lacking Tissue Inhibitor of Metalloprotease-3 Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 2812 - 2822. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Chetty, S. S. Lakka, P. Bhoopathi, S. Kunigal, R. Geiss, and J. S. Rao Tissue Inhibitor of Metalloproteinase 3 Suppresses Tumor Angiogenesis in Matrix Metalloproteinase 2-Down-regulated Lung Cancer Cancer Res., June 15, 2008; 68(12): 4736 - 4745. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Y. Mahller, S. S. Vaikunth, M. C. Ripberger, W. H. Baird, Y. Saeki, J. A. Cancelas, T. M. Crombleholme, and T. P. Cripe Tissue Inhibitor of Metalloproteinase-3 via Oncolytic Herpesvirus Inhibits Tumor Growth and Vascular Progenitors Cancer Res., February 15, 2008; 68(4): 1170 - 1179. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Dean, G. S. Butler, Y. Hamma-Kourbali, J. Delbe, D. R. Brigstock, J. Courty, and C. M. Overall Identification of Candidate Angiogenic Inhibitors Processed by Matrix Metalloproteinase 2 (MMP-2) in Cell-Based Proteomic Screens: Disruption of Vascular Endothelial Growth Factor (VEGF)/Heparin Affin Regulatory Peptide (Pleiotrophin) and VEGF/Connective Tissue Growth Factor Angiogenic Inhibitory Complexes by MMP-2 Proteolysis Mol. Cell. Biol., December 15, 2007; 27(24): 8454 - 8465. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. B. Saunders, B. L. Bohnsack, J. B. Faske, N. J. Anthis, K. J. Bayless, K. K. Hirschi, and G. E. Davis Coregulation of vascular tube stabilization by endothelial cell TIMP-2 and pericyte TIMP-3 J. Cell Biol., October 9, 2006; 175(1): 179 - 191. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. W.M. van Hinsbergh, M. A. Engelse, and P. H.A. Quax Pericellular Proteases in Angiogenesis and Vasculogenesis Arterioscler. Thromb. Vasc. Biol., April 1, 2006; 26(4): 716 - 728. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Strauss The Retinal Pigment Epithelium in Visual Function Physiol Rev, July 1, 2005; 85(3): 845 - 881. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Plaisier, K. Kapiteijn, P. Koolwijk, C. Fijten, R. Hanemaaijer, J. M. Grimbergen, A. Mulder-Stapel, P. H. A. Quax, F. M. Helmerhorst, and V. W. M. van Hinsbergh Involvement of Membrane-Type Matrix Metalloproteinases (MT-MMPs) in Capillary Tube Formation by Human Endometrial Microvascular Endothelial Cells: Role of MT3-MMP J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5828 - 5836. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H.-K. Ma, J.-Y. Yao, L.-K. Yeh, S.-T. Liang, L.-C. See, H.-T. Chen, K.-Y. Lin, C.-C. Liang, K.-K. Lin, and J.-K. Chen In Vitro Antiangiogenic Activity in Ex Vivo Expanded Human Limbocorneal Epithelial Cells Cultivated on Human Amniotic Membrane Invest. Ophthalmol. Vis. Sci., August 1, 2004; 45(8): 2586 - 2595. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-H. Yoon, Y.-J. Jung, T.-D. Kim, G. Li, B.-J. Park, J.-Y. Kim, Y.-C. Lee, J.-M. Kim, J.-I. Park, H.-D. Park, et al. Gabexate Mesilate Inhibits Colon Cancer Growth, Invasion, and Metastasis by Reducing Matrix Metalloproteinases and Angiogenesis Clin. Cancer Res., July 1, 2004; 10(13): 4517 - 4526. [Abstract] [Full Text] [PDF] |
||||
![]() |
D Atan, C Y Gregory Evans, D Louis, and S M Downes Sorsby fundus dystrophy presenting with choroidal neovascularisation showing good response to steroid treatment Br. J. Ophthalmol., March 1, 2004; 88(3): 440 - 441. [Full Text] |
||||
![]() |
C. A. Fernandez, C. Butterfield, G. Jackson, and M. A. Moses Structural and Functional Uncoupling of the Enzymatic and Angiogenic Inhibitory Activities of Tissue Inhibitor of Metalloproteinase-2 (TIMP-2): LOOP 6 IS A NOVEL ANGIOGENESIS INHIBITOR J. Biol. Chem., October 17, 2003; 278(42): 40989 - 40995. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.-P. Shi, G.K. Sukhova, M. Kuzuya, Q. Ye, J. Du, Y. Zhang, J.-H. Pan, M.L. Lu, X.W. Cheng, A. Iguchi, et al. Deficiency of the Cysteine Protease Cathepsin S Impairs Microvessel Growth Circ. Res., March 21, 2003; 92(5): 493 - 500. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. W. Spurbeck, C. Y. C. Ng, T. S. Strom, E. F. Vanin, and A. M. Davidoff Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model Blood, October 16, 2002; 100(9): 3361 - 3368. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Qi, Q. Ebrahem, K. Yeow, D. R. Edwards, P. L. Fox, and B. Anand-Apte Expression of Sorsby's Fundus Dystrophy Mutations in Human Retinal Pigment Epithelial Cells Reduces Matrix Metalloproteinase Inhibition and May Promote Angiogenesis J. Biol. Chem., April 12, 2002; 277(16): 13394 - 13400. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Baker, D. R. Edwards, and G. Murphy Metalloproteinase inhibitors: biological actions and therapeutic opportunities J. Cell Sci., January 10, 2002; 115(19): 3719 - 3727. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Lafleur, M. M. Handsley, V. Knauper, G. Murphy, and D. R. Edwards Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs) J. Cell Sci., January 9, 2002; 115(17): 3427 - 3438. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Vaillant, M. G. Chiaramonte, A. W. Cheever, P. D. Soloway, and T. A. Wynn Regulation of Hepatic Fibrosis and Extracellular Matrix Genes by the Th Response: New Insight into the Role of Tissue Inhibitors of Matrix Metalloproteinases J. Immunol., December 15, 2001; 167(12): 7017 - 7026. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Yan and M. A. Moses A Case of Tumor Betrayal : Biphasic Effects of TIMP-1 on Burkitt's Lymphoma Am. J. Pathol., April 1, 2001; 158(4): 1185 - 1190. [Full Text] [PDF] |
||||
![]() |
M. Hidalgo and S. G. Eckhardt Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy J Natl Cancer Inst, February 7, 2001; 93(3): 178 - 193. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Majka, P. McGuire, S. Colombo, and A. Das The Balance between Proteinases and Inhibitors in a Murine Model of Proliferative Retinopathy Invest. Ophthalmol. Vis. Sci., January 1, 2001; 42(1): 210 - 215. [Abstract] [Full Text] |
||||
![]() |
N. Di Girolamo, D. Wakefield, and M. T. Coroneo Differential Expression of Matrix Metalloproteinases and Their Tissue Inhibitors at the Advancing Pterygium Head Invest. Ophthalmol. Vis. Sci., December 1, 2000; 41(13): 4142 - 4149. [Abstract] [Full Text] |
||||
![]() |
J. L ASHWORTH, C. M KIELTY, and D. McLEOD Fibrillin and the eye Br. J. Ophthalmol., November 1, 2000; 84(11): 1312 - 1317. [Full Text] [PDF] |
||||
![]() |
C S SETHI, T A BAILEY, P J LUTHERT, and N H V CHONG Matrix metalloproteinase biology applied to vitreoretinal disorders Br. J. Ophthalmol., June 1, 2000; 84(6): 654 - 666. [Full Text] |
||||
![]() |
J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. Harper, G. Tamvakopoulos, and M. A. Moses Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model PNAS, April 11, 2000; 97(8): 3884 - 3889. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. H. V. Chong, R. A. Alexander, T. Gin, A. C. Bird, and P. J. Luthert TIMP-3, Collagen, and Elastin Immunohistochemistry and Histopathology of Sorsby’s Fundus Dystrophy Invest. Ophthalmol. Vis. Sci., March 1, 2000; 41(3): 898 - 902. [Abstract] [Full Text] |
||||
![]() |
M. Kamei and J. G. Hollyfield TIMP-3 in Bruch’s Membrane: Changes during Aging and in Age-Related Macular Degeneration Invest. Ophthalmol. Vis. Sci., September 1, 1999; 40(10): 2367 - 2375. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. C. Martin, J. L. Fowlkes, B. Babic, and R. Khokha Insulin-like Growth Factor II Signaling in Neoplastic Proliferation Is Blocked by Transgenic Expression of the Metalloproteinase Inhibitor TIMP-1 J. Cell Biol., August 23, 1999; 146(4): 881 - 892. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Dollery, S. E. Humphries, A. McClelland, D. S. Latchman, and J. R. McEwan Expression of Tissue Inhibitor of Matrix Metalloproteinases 1 by Use of an Adenoviral Vector Inhibits Smooth Muscle Cell Migration and Reduces Neointimal Hyperplasia in the Rat Model of Vascular Balloon Injury Circulation, June 22, 1999; 99(24): 3199 - 3205. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Butler, S. S. Apte, F. Willenbrock, and G. Murphy Human Tissue Inhibitor of Metalloproteinases 3 Interacts with Both the N- and C-terminal Domains of Gelatinases A and B. REGULATION BY POLYANIONS J. Biol. Chem., April 16, 1999; 274(16): 10846 - 10851. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Meng, V. Malinovskii, W. Huang, Y. Hu, L. Chung, H. Nagase, W. Bode, K. Maskos, and K. Brew Residue 2 of TIMP-1 Is a Major Determinant of Affinity and Specificity for Matrix Metalloproteinases but Effects of Substitutions Do Not Correlate with Those of the Corresponding P1' Residue of Substrate J. Biol. Chem., April 9, 1999; 274(15): 10184 - 10189. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Bachman, J. G. Herman, P. G. Corn, A. Merlo, J. F. Costello, W. K. Cavenee, S. B. Baylin, and J. R. Graff Methylation-associated Silencing of the Tissue Inhibitor of Metalloproteinase-3 Gene Suggests a Suppressor Role in Kidney, Brain, and Other Human Cancers Cancer Res., February 1, 1999; 59(4): 798 - 802. [Abstract] [Full Text] [PDF] |
||||
![]() |
G Cox, W P Steward, and K J O'Byrne The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer Thorax, February 1, 1999; 54(2): 169 - 179. [Full Text] |
||||
![]() |
W. Q. Liand and M. Zafarullah Oncostatin M Up-Regulates Tissue Inhibitor of Metalloproteinases-3 Gene Expression in Articular Chondrocytes via De Novo Transcription, Protein Synthesis, and Tyrosine Kinase- and Mitogen-Activated Protein Kinase-Dependent Mechanisms J. Immunol., November 1, 1998; 161(9): 5000 - 5007. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. N Fariss, S. S Apte, P. J Luthert, A. C Bird, and A. H Milam Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby's fundus dystrophy or retinitis pigmentosa Br. J. Ophthalmol., November 1, 1998; 82(11): 1329 - 1334. [Abstract] [Full Text] |
||||
![]() |
K. P. Langton, M. D. Barker, and N. McKie Localization of the Functional Domains of Human Tissue Inhibitor of Metalloproteinases-3 and the Effects of a Sorsby's Fundus Dystrophy Mutation J. Biol. Chem., July 3, 1998; 273(27): 16778 - 16781. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Bein and M. Simons Thrombospondin Type 1 Repeats Interact with Matrix Metalloproteinase 2. REGULATION OF METALLOPROTEINASE ACTIVITY J. Biol. Chem., October 6, 2000; 275(41): 32167 - 32173. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |